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ABSTRACT 
Objective 
Much of what is known about the significance of human papillomavirus (HPV) in oropharyngeal 
cancer is derived from single-institution retrospective studies, post-hoc analyses of tissue 
specimens from clinical trials, and tissue bank studies with a small sample size. The objective of 
this study is to investigate the impact of HPV on the frequency and clinical presentation of 
oropharyngeal carcinoma in a large, national sample with information from patients who 
underwent HPV testing.    
Study Design 
Retrospective, cross-sectional study. 
Methods 
We identified a comprehensive national sample of 8,359 patients with oropharyngeal carcinoma 
and known HPV status diagnosed between 2010 and 2011 within the National Cancer Data Base. 
Multivariable logistic regression was used to assess correlates of patient and tumor 
characteristics on HPV status. 
Results 
Among patients with oropharyngeal carcinoma, the frequency of HPV-related squamous cell 
carcinoma in the United States was 65.4%.  HPV-related oropharyngeal carcinoma was 
associated with younger age, male sex, and white race (P<0.001). Advanced primary tumor stage 
was associated with HPV-negative disease (P<0.001), while increasing nodal burden was 
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associated with HPV-positive disease (P<0.001).  Despite less advanced nodal disease, HPV-
negative tumors were associated with a higher likelihood of metastasis at presentation (P<0.001).   
Conclusion 
HPV now accounts for the majority of newly diagnosed oropharyngeal carcinoma in the United 
States and is associated with a distinct clinical profile, supporting efforts to re-evaluate the 
staging and treatment paradigm for HPV-associated oropharyngeal cancer.  
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Introduction 
Over the past three decades, the incidence of oral cavity, laryngeal, and hypopharyngeal cancers 
has been declining in the United States,
1
 concurrent with a decrease in tobacco use over this time 
frame. In contrast, the incidence of oropharyngeal squamous cell carcinoma (OPC) has been on 
the rise, predominately among white men less than 60 years of age, both in the United States
1
 
and in other economically developed countries in North America
2, 3
 and Western Europe.
2, 4–6
 
Epidemiologic and molecular studies have shown this site-specific increase in oropharyngeal 
cancer incidence to be attributable to infection with high-risk human papillomavirus (HPV), 
particularly oncogenic HPV subtype 16, resulting in a distinct neoplastic entity.
1, 7
 A recent 
systematic r view comprised predominately of studies from North America and Europe, 
demonstrated a significant increase in the percentage OPCs attributable to HPV over time, from 
40.5% before 2000, to 64.3% between 2000 and 2004, to 72.2% between 2005 and 2009.
8
 In 
addition, retrospective analyses of clinical trial populations from North America, Europe, 
Australia and New Zealand from 2002 to 2005 report HPV incidence rates of 57.3% and 63.8% 
among 185 and 323 patients with stage III to IV OPC, respectively.
9, 10
 
 
These same studies show that the presence of HPV is a favorable independent prognostic factor 
for overall survival.
9–12
 Case studies have also shown that individuals with HPV-associated OPC 
demonstrate unique clinical and behavioral characteristics, including younger age at presentation, 
white male predominance, and a greater number of oral sex partners.
12–15
 In contrast, HPV-
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negative OPC is associated with tobacco and alcohol exposure with the strength of the 
association increasing with the intensity and duration of use.
13
 A difference in the distribution of 
primary tumor and nodal classification between HPV-positive and HPV-negative carcinomas has 
also been described.  
 
However, much of what is known about the significance of HPV in oropharyngeal cancer is 
derived from single-institution retrospective studies,
7, 13
 post-hoc analyses of tissue specimens 
from clinical trials,
9–11, 16
 and one study with prospective evaluation of HPV in a subset of 96 
patients enrolled on a clinical trial.
12
 These studies are limited by small sample size, restrictive 
eligibility criteria of prospective trials, and heterogeneity of the study population due to inclusion 
of multiple primary cancer sites. For example, an analysis of tissue specimens from 271 patients 
from the Iowa, Hawaii, and Los Angeles SEER regions demonstrated prevalence of HPV-related 
disease of 72% during 2000-2004.
1
 Very similar results were observed in an analysis of 203 
tonsillar cancer specimens from Sweden.
4
 The generalizability of these studies is limited by their 
small sample size and nonrepresentativeness of tested patients. Other epidemiologic studies 
defined “potentially HPV-associated cancers” based on the anatomical subsite of disease,
2, 17, 18
 
but did not have information on the HPV status of tumor tissues.  
 
While the changing epidemiology of OPC has been well documented, population level data on 
the frequency and clinical features of HPV-related OPC are lacking. There has not yet been an 
analysis of HPV-associated OPC in a large, national sample with information from patients who 
underwent HPV testing. This study seeks to describe the influence of HPV status on clinical 
presentation on a national level.   
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Methods 
Data Source and Study Population 
The National Cancer Data Base (NCDB) is a nationwide, facility-based, oncology database of 
the American College of Surgeons Commission on Cancer (CoC) that currently captures 70% of 
all new cancer diagnoses in the United States annually from over 1,400 Commission-accredited 
cancer programs across a diverse range of geographic regions. Data are abstracted by trained 
tumor registrars and reported using national established protocols coordinated though the North 
American Association of Central Cancer Registries. Ongoing data quality-assurance assessments 
are performed using both automated electronic checks and external site surveyors.
19
 As no 
patient, physician, or hospital identifiers were examined in this study, exemption was granted by 
the University of Michigan Institutional Review Board. 
 
The International Classification of Disease for Oncology, third edition (ICD-0-3), was used to 
identify 22,494 patients within the NCDB who were diagnosed between January 1, 2010 and 
December 31, 2011 with primary carcinoma of the oropharynx. The data query was restricted to 
2010-2011 to coincide with availability of HPV data from the NCDB. Cases were identified 
using ICD-0-3 topography codes C01.9, C02.4 (base of tongue), C09.0-09.1, C09.8-09.9 (tonsil), 
C05.1-05.2, C10.0, C10.2-10.4, C10.8-10.9 (other oropharynx). Tumor histology was limited to 
ICD-0 codes for squamous histology [n = 21,796; 805 (papillary carcinoma, NOS), 807 
(squamous cell carcinoma NOS), and 808 (lymphoepthelial carcinoma)]. Patients with data 
missing on sex (n=0), hospital identification (n=0), geographic region (n=0), and HPV status 
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(n=13,437) were excluded. The analytic cohort comprised of a total of 8,359 patients who met 
the aforementioned study criteria.   
 
Measures 
Patient-level independent variables included age at diagnosis, sex, race, ethnicity, comorbidity 
score, household income, educational attainment, and insurance status. Patient race was 
categorized by the NCDB as white, black, Asian/Pacific Islander, and Native American. Due to 
small numbers Asian/Pacific Islander and Native American were collapsed into an “other” 
category. Patient ethnicity was categorized independent of race as either non-Hispanic or 
Hispanic. The Charlson-Deyo comorbidity score was used to identify comorbid conditions 
within the cohort. Household income and educational attainment are area-level measures based 
on the patient’s zip code at time of diagnosis with data drawn from the 2000 US census. 
Insurance status was defined by the patient’s primary insurance carrier at the time of diagnosis 
and/or treatment and categorized as private including government, Medicare, Medicaid, and 
uninsured.  Geographic location was determined by the location of the diagnosing facility within 
the 4 designated US census regions. 
 
Primary tumor (T), nodal (N), and metastasis (M) classification was categorized clinically 
according to the definitions used by the American Joint Committee on Cancer (AJCC), seventh 
edition. In cases where clinical T and/or N classification was either missing or unknown (11.5% 
and 5.0% for T- and N-, respectively), pathologic staging was used. Stage was recoded into stage 
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I, II, III, IVA/B, and IVC using the American Joint Committee on Cancer’s (AJCC) AJCC 
Cancer Staging Manual, 7
th
 edition. 
 
Statistical Analyses 
Distributions of clinical, non-clinical, and tumor characteristics between HPV-positive and HPV-
negative tumors were compared using χ
2
 test for categorical variables and t test for continuous 
variables. Multivariable logistic regression was used to determine factors associated with HPV 
status. Because of substantial missingness in tumor grade, we conducted analyses both with and 
without tumor grade as a covariate in the model, and the results were similar. Multicollinearity 
was assessed using the generalized variance inflation factor (GVIF). All statistical tests were 
performed using R 3.1.1. The GVIFs were calculated in R with R package “Car”. Two sided tests 
yielding p < 0.05 were considered as statistically significant. 
 
Results 
A total of 21,796 patients with OPC were identified before applying the exclusion criteria. The 
final analytic cohort consisted of 8,359 patients diagnosed with squamous cell carcinoma of the 
oropharynx between 2010 and 2011.   
 
Table 1 summarizes the clinical, non-clinical, and tumor characteristics of the study population 
and distribution by tumor HPV status. The mean age was 58.4 years (range, 20 to 90 years). The 
overwhelming majority of patients were male (82.2%), white (91.4%), non-Hispanic (96.8%), 
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and had no associated comorbidity (83.0%). Tumors typically arose within the base of tongue or 
tonsils (91.3%) and most patients presented with locally advanced stage III/IV disease (85%).   
 
The frequency of HPV-related OPC in the present cohort was 65.4%.  The proportion of HPV-
related OPC was highest among young, white, non-Hispanic, males. Among patients ages 18 to 
49 with OPC, HPV-related disease was observed in 69.7% compared to 68.5% among patients 
ages 50 to 64 and 55.2% among patients ages 65 and older. The proportion of HPV-related OPC 
was significantly higher among whites (67.4%) as compared to blacks (43.1%), Asians (46.8%), 
and American Indians/Eskimos (42.9%) (P < 0.001). HPV-related OPC was also higher among 
non-Hispanics compared to Hispanics (65.6% vs. 55.5%, P < 0.001) and among men compared 
to women (67.5% vs. 55.7%, P < 0.001).   
 
Compared to patients with HPV-negative tumors, patients with HPV-positive tumors were 
significantly younger (mean age 57.5 vs. 60.1 years, P < 0.001) and more likely to be male (P < 
0.001), whit  (P < 0.001), hold private insurance (P < 0.001), graduate from high school (P < 
0.001), and have a higher household income (P < 0.001) (figure 1). Geographically, patients with 
HPV-negative OPC were most likely to be diagnosed in the South. 
 
Compared to non-HPV-related OPC, HPV-positive tumors more commonly originated in the 
tonsil (P < 0.001) and were poorly differentiated (P < 0.001). Patients with HPV-positive tumors 
were more likely to present with earlier T-classification (T1-2, 76% vs. 62%; P < 0.001) and 
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more advanced nodal disease (N2-3, 68% vs. 56%; P < 0.001) than patients with HPV-negative 
tumors (figure 2). Despite less advanced nodal disease, HPV-negative tumors were associated 
with a higher likelihood of metastatic disease at presentation (4.2% vs. 1.7%, P < 0.001).   
 
In multivariable logistic regression analyses, age, sex, race, ethnicity, insurance status, education, 
geographic location, primary tumor site, tumor grade, and TNM classification remained 
significant determinants for HPV status (Table 2). Younger age and male sex were significantly 
associated with HPV-positive tumors (for younger age, 18 to 49 years odds ratio [OR], 1.39; 
95% confidence interval [CI], 1.13-1.72; 50 to 64 years, OR, 1.34; 95% CI 1.13-1.59; and for 
male sex, OR, 1.52; 95% CI, 1.33-1.75). Non-white race (black race, OR, 0.54; 95% CI, 0.44-
0.66 and other race, OR, 0.49; 95% CI 0.33 to 0.73), Hispanic ethnicity (OR, 0.69; 95% CI, 0.51- 
0.93), absence of a high-school education (14% to 28.9% and ≥ 29% not graduating high school, 
OR 0.82; 95% CI, 0.72-0.94 and OR, 0.71; 95% CI 0.58-0.88, respectively), and residence in the 
South (OR, 0.77; 95% CI 0.67-0.89) were associated with HPV-negative tumors. Patients 
without private insurance were more likely to have HPV-negative tumors (Uninsured/Medicaid 
OR 0.50; 95% CI, 0.43-0.59; Medicare OR, 0.74; 95% CI, 0.63-0.88). There was a statistically 
significant difference in HPV status by primary site of origin within the oropharynx, with HPV 
negative tumors more likely to arise in the base of tongue (OR, 0.72; 95% CI 0.65-0.81) and 
other oropharyngeal sites (OR, 0.37; 95% CI 0.31-0.45) as compared to the tonsils. Advanced 
primary tumor classification was associated with HPV-negative disease (T3, OR, 0.70; 95% CI 
0.59-0.82; T4, OR, 0.59; 95% CI 0.50-0.71 [T1 = reference]), while nodal involvement was 
associated with HPV-positive disease (N1, OR 1.80, 95% CI 1.52-2.14; N2, OR 2.25, 95% CI 
1.96-2.58; N3, OR 2.07, 95% CI 1.55-2.77 [N0 = reference]). HPV-negative tumors were 
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associated with a higher likelihood of metastatic disease at presentation (OR, 0.56, 95% CI 0.39-
0.79).  
 
Discussion 
The results of this study provide insight into the frequency and clinical presentation of HPV-
related orophargyneal cancer in the United States on a population level. Using a large, national 
hospital-based cancer registry, we observed an association with HPV in 65.4% of all newly 
diagnosed oropharyngeal carcinomas in 2010 and 2011 in the United States. HPV-positive 
tumors were associated with a distinct clinical profile, including younger age, male sex, white 
race, earlier primary tumor classification (T1-2), more advanced nodal classification (N2-3), and 
lower likelihood of metastatic disease at presentation.   
 
While the increasing incidence of OPC has been well documented both in the United States
1
 and 
in other economically developed countries in North America
2, 3
 and Western Europe,
2, 4–6
 the true 
incidence of HPV-related OPC and associated clinical characteristics have not been well 
characterized on a national level. Retrospective analyses of clinical trial populations from 2002 
to 2005 report HPV incidence rates of 57.3% and 63.8% among 185 and 323 patients with 
locally advanced, stage III to IV, OPC, respectively,
9, 10
 whereas North American single 
institutional series have reported rates as high as 75% to 93%.
20–22
 Data from 3 Surveillance, 
Epidemiology, and End Results (SEER) registries in the United States demonstrate a substantial 
increase in HPV-related OPC from 16.3% during the 1980s to 71.7% during the 2000s.
1
  
However, these rates were determined from a limited sample size, with HPV status available for 
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only 271 tumor specimens over a 20 year period.
1
 Our study provides strong confirmation that 
the recent changes in the population-level incidence of OPC in the United States are attributable 
to HPV infection with an overall HPV frequency of 65.4% during 2010 to 2011 based on over 
8,000 patients with newly diagnosed OPC. These findings provide the most representative data 
on HPV-related OPC for the US population to date.   
 
In addition, our data extend prior retrospective observations from clinical trial populations
9, 10
 
and single institutions
7, 13
 that HPV-related OPC is a distinct clinical disease entity by showing 
that clinical differences persist on a population level between individuals with HPV-positive and 
negative disease.  Consistent with other reports, we found younger age, male sex, and white race 
to be significantly associated with HPV-positive tumors. A major limitation of prior studies 
reporting racial differences in the percentage OPC attributable to HPV, primarily in blacks, is 
inadequate racial representation with the total number of black patients in these studies ranging 
from 28 to 49.
1, 14, 23, 24
 Furthermore, these previous studies have provided information on the 
percentage of OPCs attributable to HPV in other racial groups such as Asians/Pacific Islanders or 
in patients of Hispanic ethnicity. Owing to our large sample size, we were able to show that the 
proportion of HPV-related OPC was significantly higher among whites (67.4%) as compared to 
blacks (43.1%), Asians (46.8%), and American Indians/Eskimos (42.9%). A similar finding was 
present between non-Hispanics (65.6%) and Hispanics (55.5%). These differences have been 
hypothesized to be due in part to racial variations in sexual behaviors with studies suggesting 
that a higher proportion of whites engange in oral sex, which has been linked to HPV 
transmission.
13, 25
 However, it is important to note that the current epidemic of HPV-related OPC 
is not exclusive to white males. 
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Geographically, we found that a disproportionate number of HPV-negative OPCs were located in 
the South, mirroring the higher rates tobacco and alcohol use in this region. 
 
Patients with HPV-positive OPC were more likely to present with small primary tumors (T1-2: 
75.6% vs. 62.2%) and more advanced nodal disease (N2-3: 67.8% vs 56.1%), which is consistent 
with previously reported single institution data from Princess Margaret Hospital (T1-2: 56% vs 
49%; N2b-3: 69% vs 46%)
20
 as well as secondary analysis of the Trans Tasman Radiation 
Oncology Group (TROG 02.02) series of 185 patients (T1-2: 37% vs 15%; N2-3 86% vs 65%).
9
  
In contrast, in a series of 111 patients with locally advanced OPC enrolled on TAX-324,
11
 
patients with HPV-positive carcinoma were more likely to have smaller primary tumors (T1-2: 
49% vs 20%), but there was not difference in nodal status between the two groups. A similar 
finding was present in patients enrolled on RTOG 0129.
10
 The discrepancy in nodal presentation 
among these various prospective trials likely stems from their restrictive eligibility criteria and 
thereby limits the generalizability of these studies to the OPC population at large. Our findings 
on the association of HPV-related OPC with earlier primary tumor classification (T1-2) and 
more advanced nodal classification (N2-3) provide the most representative data on the 
presentation of HPV-related OPC to date.   
 
In addition, we found that despite more extensive nodal disease, patients with HPV-positive OPC 
were less likely to present with metastatic disease at diagnosis. It is unclear if this difference in 
the rate metastasis at presentation is attributable to tumor biology, delayed care secondary to 
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socioeconomic disparities between patients with HPV-positive and negative tumors, or a 
combination of the two. For instance, we found that patients with HPV-negative tumors were 
more likely to be of black race, uninsured, and have a lower education level compared to those 
with HPV-positive tumors. Studies have found these factors to be associated with a greater 
likelihood of presenting with late-stage cancer at diagnosis across multiple disease sites.
26, 27
 
Following treatment, the rate of distant metastases between HPV-positive and HPV-negative 
tumors is similar, though these studies suggest that patients with HPV-positive OPC may 
develop metastases at a longer interval and have a higher proportion of the recurrences at distant 
sites.
28, 29
 
 
HPV status has recently been recognized as a significant independent prognostic factor in 
patients with OPC with multiple retrospective analyses of prospective clinical trials 
demonstrating improved overall survival and locoregional control for patients with locally-
advanced HPV-positive OPC compared to similarly treated patients with HPV-negative 
disease.
9–11, 29
 Overall survival for these patients with stage III-IV HPV-positive and HPV-
negative  tumors was 91% versus 74% (HR 0.36) at 2-years on TROG 02.02
9
 and 82% versus 
35% (HR 0.2) at 5-years on TAX 324.
11
 While there is currently insufficient information to alter 
therapy based on HPV status off clinical trial, treatment de-intensification is currently being 
explored for subpopulations of patients with locally-advanced HPV-positive OPC (T1-3, N0-2c) 
because of their favorable prognosis.
20
 Given the increasing incidence of OPC secondary to the 
HPV epidemic and the favorable prognosis of this younger, healthier population, developing 
strategies to optimize post-treatment quality of life (QOL) is imperative.   
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There are several limitations to this study, most notably the number of exclusions due to missing 
HPV status. Ideally, the NCDB would have more complete representation of the variables 
included within the database. The adequacy of the NCDB for evaluating clinical characteristics 
in head and neck oncology on a national level might be evaluated in a separate dedicated analysis 
to fully explore the quality of the data and the influence of the large amount of missing data. 
Second, hospital differences in the method of HPV detection may yield discrepant results, 
depending on whether in-situ hybridization or immunohistochemistry was used.
30
 The NCDB 
does not provide information on the HPV detection method. However, it should be noted that 
national consensus on assay methodology is lacking. Finally, owing to the nature of data 
reporting in the NCDB, survival outcomes for the patients included in the present study are 
unavailable, limiting our ability to evaluate the impact of differences in HPV-status on clinical 
outcomes on a national level. These limitations are countered by the strengths of the study 
including its large size, national sample, and availability of information on HPV-status. 
 
The results of this study show that HPV now accounts for the majority of newly diagnosed OPCs 
in the United States and that HPV-related OPC is associated with a distinct clinical profile, 
including younger age, male sex, white race, earlier primary tumor classification, more advanced 
nodal classification, and a lower likelihood of distant metastatic disease at presentation. 
However, it is important to note that the current epidemic of HPV-related OPC is not limited to 
white men. These findings have important implications for cancer prevention strategies, 
Page 16 of 28
John Wiley & Sons
The Laryngoscope
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
17 
 
including prophylactic HPV vaccination, and lend support for efforts to re-evaluate the staging
31, 
32
 and treatment paradigm
20, 33
 for HPV-associated oropharyngeal cancer. 
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Figure Legends 
Figure 1.  Patient characteristics stratified by human papillomavirus (HPV) status. 
Figure 2.  Clinical TNM presentation stratified by human papillomavirus (HPV) status.  (A) 
Primary tumor classification.  (B) Nodal classification.  (C) Metastasis classification. 
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Table 1.  Distribution of patient and tumor characteristics by HPV status  
 
 
Overall 
(n=8359) 
HPV-positive 
(n=5466, 65.4%) 
HPV-negative 
(n=2893, 34.6%) 
P value* N % N % N % 
Patient characteristics        
Sex       <0.001 
     Male 6869 82.2 4636 84.8 2233 77.2  
     Female 1490 17.8 830 15.2 660 22.8  
Age, y       <0.001 
     18-49 1474 17.6 1028 18.8 446 15.4  
     50-64 4781 57.2 3276 59.9 1505 52.0  
      ≥ 65 2104 25.2 1162 21.3 942 32.6  
Race       <0.001 
     White 7553 91.4 5083 94.2 2470 86.2  
     Black 575 7.0 248 4.6 327 11.4  
     Other 132 1.6 63 1.2 69 2.4  
Ethnicity       <0.001 
     Non-hispanic 7761 96.8 5093 97.3 2668 95.9  
     Hispanic 254 3.2 141 2.7 113 4.1  
Charlson-deyo comorbidity score       <0.001 
     0 6935 83.0 4613 84.4 2322 80.3  
     1 1133 13.6 690 12.6 443 15.3  
     ≥ 2 291 3.5 163 3.0 128 4.4  
Insurance       <0.001 
     Uninsured 396 4.8 203 3.8 193 6.8  
     Medicaid 639 7.8 315 5.9 324 11.4  
     Medicare 2159 26.2 1207 22.4 952 33.5  
      Private 5037 61.2 3662 68.0 1375 48.4  
Education        
      <14% not graduating high school 3215 41.2 2257 44.3 958 35.3 <0.001 
      14%-28.9% not graduating high school 3562 45.6 2284 44.9 1278 47.0  
      ≥ 29% not graduating high school 1031 13.2 549 10.8 482 17.7  
Household income       <0.001 
      < $30,000 888 11.4 474 9.3 414 15.2  
      $30,000-45,999 3438 44.0 2206 43.3 1232 45.3  
      $46,000+ 3482 44.6 2410 47.4 1072 39.4  
Geographic location       <0.001 
      Northeast 1915 22.9 1272 23.3 643 22.2  
      Midwest 2125 25.4 1496 27.4 629 21.7  
      South 2990 35.8 1788 32.7 1202 41.6  
      West 1329 15.9 910 16.7 419 14.5  
Tumor characteristics        
Year of diagnosis       0.043 
      2010 3182 38.1 2124 38.9 1058 36.6  
      2011 5177 61.9 3342 61.1 1835 63.4  
Primary site       <0.001 
      Base of tongue 3407 40.8 2167 39.7 1240 42.9  
      Tonsil 4224 50.5 2987 54.6 1237 42.8  
      Other oropharyngeal site 728 8.7 312 5.7 416 14.4  
Grade       <0.001 
      Well differentiated 255 4.0 113 2.7 142 6.4  
      Moderately differentiated  2722 42.3 1629 38.8 1093 48.9  
      Poorly differentiated  3455 53.7 2454 58.5 1001 44.8  
T classification       <0.001 
      T1 2539 31.8 1818 34.6 721 26.4  
      T2 3132 39.3 2154 41.0 978 35.8  
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      T3 1305 16.4 772 14.7 533 19.5  
      T4 1004 12.6 505 9.6 499 18.3  
N classification       <0.001 
      N0 1447 17.6 719 13.4 728 25.8  
      N1 1528 18.6 1015 18.9 513 18.2  
      N2 4900 59.7 3443 64.0 1457 51.6  
      N3 330 4.0 203 3.8 127 4.5  
M classification       <0.001 
      M0 8088 97.4 5345 98.3 2743 95.8  
      M1 213 2.6 92 1.7 121 4.2  
AJCC stage       <0.001 
      I 441 5.5 217 4.1 224 8.2  
      II 550 6.9 301 5.7 249 9.1  
      III 1568 19.6 1035 19.7 533 19.4  
      IVA/B 5222 65.3 3607 68.7 1615 58.9  
      IVC 213 2.7 92 1.7 121 4.4  
 
Variables with missing data are as follows: race (n=99; 1.2%), ethnicity (n=344; 4.1%), insurance (n=128; 1.5%), household income (n=551; 
6.6%), education (n=551; 6.6%), tumor grade (n=1927; 23%), primary tumor classification (n=379, 4.5%), nodal classification (n=154, 1.8%), 
metastasis classification (n=58, 0.7%), stage (n=365, 4.4%).   
Missing data were similarly distributed between HPV+ and HPV- patients for all variables. 
 
*Missing data were excluded from P-value calculations. 
 
Abbreviations:  HPV, human papillomavirus; AJCC, American Joint Committee on Cancer 
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Table 2.  Multivariable analysis of factors associated with HPV status 
 Unadjusted Adjusted 
Variable OR 95% CI P value OR (95% CI) P value 
Sex       
     Male 1 [Reference]  1 [Reference]  
     Female 0.57 (0.50-0.65) <0.001 0.66 (0.57-0.75) <0.001 
Age, y       
     18-49 1.79 (1.53-2.09) <0.001 1.39 (1.13-1.72) 0.002 
     50-64 1.74 (1.55-1.96) <0.001 1.34 (1.13-1.59) 0.001 
      ≥ 65 1 [Reference]  1 [Reference]  
Race       
     White 1 [Reference]  1 [Reference]  
     Black 0.37 0.30-0.44 <0.001 0.54 (0.44-0.66) <0.001 
     Other 0.46 0.31-0.67 <0.001 0.49 (0.33-0.73) 0.001 
Ethnicity       
     Non-hispanic 1 [Reference]  1 [Reference]  
     Hispanic 0.62 0.47-0.82 0.001 0.69 (0.51-0.93) 0.013 
Charlson-deyo comorbidity score       
     0 1 [Reference]  1 [Reference]  
     ≥ 1 0.73 (0.64-0.83) <0.001 0.94 (0.91-1.08) 0.37 
Insurance       
     Private 1 [Reference]  1 [Reference]  
     Medicare 0.48 (0.43-0.54) <0.001 0.74 (0.63-0.88) <0.001 
     Uninsured/Medicaid 0.36 (0.31-0.42) <0.001 0.50 (0.43-0.59) <0.001 
Education       
      <14% not graduating high school 1 [Reference]  1 [Reference]  
      14%-28.9% not graduating high school 0.75 (0.68-0.84) <0.001 0.82 (0.72-0.94) 0.005 
      ≥ 29% not graduating high school 0.49 (0.42-0.58) <0.001 0.71 (0.58-0.88) 0.002 
Household income       
      < $30,000 0.52 (0.44-0.61) <0.001 1.00 (0.80-1.25) 0.99 
      $30,000-45,999 0.82 (0.73-0.91) <0.001 1.09 (0.95-1.26) 0.23 
      $46,000+ 1 [Reference]  1 [Reference]  
Facility location       
      Northeast 1 [Reference]  1 [Reference]  
      Midwest 1.20 (1.04-1.39) 0.014 1.10 (0.94-1.29) 0.23 
      South 0.75 (0.66-0.86) <0.001 0.77 (0.67-0.89) <0.001 
      West 1.12 (0.95-1.32) 0.19 1.03 (0.86-1.23) 0.73 
Primary site       
      Tonsil 1 [Reference]  1 [Reference]  
      Base of tongue 0.71 (0.64-0.79) <0.001 0.72 (0.65-0.81) <0.001 
      Other oropharyngeal site 0.29 (0.24-0.35) <0.001 0.37 (0.31-0.45) <0.001 
Grade       
      Well/moderately differentiated 1 [Reference]  1 [Reference]  
      Poorly differentiated  1.78 (1.59-2.00) <0.001 1.62 (1.44-1.88) <0.001 
      Unspecified  1.46 (1.28-1.67) <0.001 1.42 (1.23-1.64) <0.001 
T classification       
      T1 1 [Reference]  1 [Reference]  
      T2 0.88 (0.78-1.00) 0.05 0.94 (0.82-1.07) 0.34 
      T3 0.56 (0.48-0.66) <0.001 0.70 (0.59-0.82) <0.001 
      T4 0.40 (0.34-0.47) <0.001 0.59 (0.50-0.71) <0.001 
N classification       
      N0 1 [Reference]  1 [Reference]  
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      N1 2.02 (1.71-2.38) <0.001 1.80 (1.52-2.14) <0.001 
      N2 2.42 (2.12-2.76) <0.001 2.25 (1.96-2.58) <0.001 
      N3 1.67 (1.28-2.19) <0.001 2.07 (1.55-2.77) <0.001 
M classification       
      M0 1 [Reference]  1 [Reference]  
      M1 0.40 (0.29-0.56) <0.001 0.56 (0.39-0.79) 0.001 
 
Year of diagnosis did not demonstrate statistical significance on multivariable analysis (data not shown). 
 
Abbreviations:  HPV, human papillomavirus; OR, Odds Ratio;  CI, Confidence interval 
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